New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization

New 3-substituted oxindole derivatives were designed and synthesized as antiproliferative agents. The antiproliferative activity of compounds 6a–j was evaluated against 60 NCI cell lines. Among these tested compounds, compounds 6f and 6g showed remarkable antiproliferative activity, specifically against leukemia and breast cancer cell lines. Compound 6f was the most promising antiproliferative agent against MCF-7 (human breast cancer) with an IC 50 value of 14.77 µM compared to 5-fluorouracil (5FU) (IC 50 = 2.02 µM). Notably, compound 6f hampered receptor tyrosine EGFR fundamentally with an IC 50 value of 1.38 µM, compared to the reference sunitinib with an IC 50 value of 0.08 µM. Moreover, compound 6f afforded anti-tubulin polymerization activity with an IC 50 value of 7.99 µM as an outstanding observable activity compared with the reference combretastatin A4 with an IC 50 value of 2.64 µM. In silico molecular-docking results of compound 6f in the ATP-binding site of EGFR agreed with the in vitro results. Besides, the investigation of the physicochemical properties of compound 6f via the egg-boiled method clarified good lipophilicity, GIT absorption, and blood–brain barrier penetration properties.